Healthcare’s Next Source of Alpha Is Moving Upstream
The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns.
Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Ipsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Better
Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approach to restoring the function of p53, a tumor-suppressing protein.
Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product.
The AI Funding Divide: Why VCs Will Miss the Next Healthcare Category Kings (And Where CEOs Should Look Instead)
While AI makes VC faster, it’s not necessarily wiser. In healthcare, where breakthroughs rarely resemble anything the market has seen before, that distinction is everything.
Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching Instead
What matters just as much — if not more — is everything around that number: how customers adopt the product, how sales actually happen, and whether the company is building something that can scale inside a complex, regulated system.
presented by
New Webinar: The Payer AI Readiness Gap: Why Better Data Will Define the Next Era of Health Plan Performance
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
Two New Takes on Making a Type of Targeted Cancer Therapy Even Better
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.
Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products
Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.
Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M
Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Valuing Early-Stage Life Sciences Companies: The Why, the How, and the Impact
Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.
Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets
Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.
UPMC Enterprises’ Biopharma Lead: We are At a Tipping Point When it Comes to China
Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore.
10 Key MedTech Themes for 2026
In today's dynamic environment, companies are navigating deal-making and innovation spurred by the vertical integration of AI and a rebounding IPO market. Here are ten global trends poised to define the industry in the coming year.
Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics
Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.